11:00:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska - samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo.

Kalender

2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-02 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2021-05-06 09:45:16
Oslo May 6, 2021 - Observe Medical ASA (OSE: OBSRV), announces that Sippi®
automated and digital urine meter recently received new patent approvals in
India, China and Brazil, further expanding and strengthening the global patent
protection for Sippi® proprietary technology.

"We are pleased to announce that Sippi® since end March this year, has received
three important patent approvals - in India, China and Brazil respectively, for
SippCoat® and SippSense® proprietary technologies, thus further strengthening
the patent protection and supporting the current commercial rollout in Europe as
well as the planned expansion into North America and Asia," says Björn Larsson,
CEO Observe Medical.

Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer (SippLinkT) to the hospital patient data
management systems and detects (SippSense®) and hinders (Sippcoat®) biofilm
formation, that can lead to urinary infections. Sippi® patent protection
comprise five patent families and over 60 individual approved patients in
Europe, US / North America and in Asia.

Observe Medical current focus is the clinical rollout of Sippi® in the Nordic
region and selected countries in rest of Europe to get systems in clinical use,
and to receive customer feedback.

"COVID-19 pandemic is highlighting the need for increased efficiency in
intensive care units and other departments in hospitals, as well as the need for
accurate patient data, and to prevent and manage hospital acquired infections.
Sippi® is an innovative solution addressing these major challenges, enabled by
the proprietary SippSense®, SippCoat® and SippLink® technologies.

"The most recent patent approvals in India, China and Brazil are further
strengthening the patent protection of the Sippi® system, including the
possibility to apply the SippCoat® technology in other applications, further
expanding the commercial opportunity", Larsson concludes.

For further information, please contact:

Björn Larsson, CEO, mobile: +46 76 620 17 25, E-mail:
bjorn.larsson@observemedical.com

About Observe Medical https://observemedical.com/

Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders biofilm formation that can lead to urinary infections
(Sippcoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.